Warning
Imprimis NJOF Recalls Tri-Moxi+¿
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0251-2026Drug / Pharmaceutical
Imprimis NJOF Recalls Tri-Moxi+¿
Imprimis NJOF, LLC · Class II — Moderate Risk
Product Description
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Reason for Recall
Presence of particulate matter - Glass like particles.
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
U.S Nationwide
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. Imprimis NJOF, LLC initiated the recall on December 18, 2025 affecting 314 boxes of 6,280 pre-filled syringes. Presence of particulate matter - Glass like particles. The product was distributed in U.S Nationwide. Consumers should check their purchases and discontinue use of any affected product. Contact Imprimis NJOF, LLC for further instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination.